German opposition party finds no unity in gene technology debate
This article was originally published in Clinica
Executive Summary
Conservative parties forming the opposition in Germany have seized the opportunity offered by Federal President Johannes Rau's intervention on gene technology (see Clinica No 959, p 7) and have issued position papers on the ongoing debate. Their haste is no doubt motivated by next year's general election. But it is noteworthy that the Social Democratic Party (SPD) has still to deliver an official opinion on the subject.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.